Pfizer’s $4.9bn bet on obesity startup Metsera is looking promising, with 14.1% weight loss reported in a Phase IIb trial. In the VESPER-1 trial (NCT06712836), MET-097i, a glucagon-like peptide-1 ...
U.S. pharmaceutical company Eli Lilly announced on the 11th that its new obesity treatment drug ‘retatrutide (retatrutide)’ under development demonstrated excellent weight loss effects in Phase 3 ...
Amgen Inc (NASDAQ:AMGN) announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate ...
News Medical on MSN
George Mason University leads phase 2 clinical trial for pill to help maintain weight loss after GLP-1s
GLP-1 medications like Ozempic and Wegovy have transformed obesity treatment, but maintaining weight loss after the medications stop remains a challenge. George Mason University is leading a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback